Arbutus Biopharma (ABUS) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arbutus Biopharma is set to release its third quarter 2024 financial results and provide a corporate update on November 6, 2024. The company continues to advance its promising therapeutics for chronic hepatitis B, with key treatments in various stages of clinical trials. Investors and stakeholders can anticipate insights into the progress of their innovative RNAi therapeutic and PD-L1 inhibitor.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.